Investigational Anti-PD-1 Agent Shows Potential for Treatment of Unresectable or Metastatic MSI-H/dMMR Solid Tumors

The novel checkpoint inhibitor HLX10 showed positive safety and efficacy in a phase 2 clinical trial in patients with microsatellite instability-high or mismatch repair deficient solid tumors, including gastric cancer.